Margaret Byrne, MD
Medical Oncology · Iowa City, IANPI 1295027696
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $1,260 of the $1,294 with a category attached, or 97.4%. Jazz Pharmaceuticals Inc. accounts for 97.4% of it on its own, with 2 other manufacturers making up the rest.
Across 3 payments — averaging $431.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Jazz Pharmaceuticals Inc.$1K
- Servier Pharmaceuticals LLC$23
- Merck$11
Across 7 payments — averaging $29,688 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AstraZeneca$118K
- Biontech SE$52K
- Merck$33K
- Pfizer$4K
What the payments were for
- Consulting fees$1,26097%
- Food & beverage$232%
- Education$111%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Jazz Pharmaceuticals Inc. | 1 | $1,260 |
| Servier Pharmaceuticals LLC | 1 | $23 |
| Merck | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ZEPZELCA$1,260
How this compares
$1,294 in reported general payments places this provider in the 55th percentile of 47 medical oncology providers in Iowa.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TagrissoOsimertinib Mesylate | 15 | $248,733 |
| Enoxaparin Sodium | 12 | $4,505 |
| Prochlorperazine Maleate | 43 | $343 |
| Nystatin | 11 | $263 |
| Ondansetron Hcl | 55 | $227 |
| Mirtazapine | 12 | $190 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 11 | $161 |
| Prednisone | 43 | $142 |
| Dexamethasone | 25 | $112 |
| Levothyroxine Sodium | 33 | $97 |
| Olanzapine | 21 | $88 |
| Omeprazole | 11 | $70 |
| Oxycodone Hcl | 11 | $66 |
| Fluoxetine Hcl | 13 | $0 |
Paid to pharmacies, not to this prescriber.
Other medical oncology in Iowa City
- Jun ZhangIowa City$377K
- John RiethIowa City$11K
- Mark BurkardIowa City$10K
- Fernando Maciel BarbosaIowa City$3K
- Gustavo Fernandes Godoy AlmeidaIowa City$2K
- Naomi FeiIowa City$1K
- Saima SharifIowa City$122
- Susan RoederIowa City$47
- Margarida SilvermanIowa City$0
- Tara GraffClive$702K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.